You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DHODH

Showing 1 - 23 of 23
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

SARS-CoV-2 Infection Trial in India (RP7214 + Standard of care (SOC), Placebo + Standard of care (SOC))

Completed
  • SARS-CoV-2 Infection
  • RP7214 + Standard of care (SOC)
  • Placebo + Standard of care (SOC)
  • Bangalore, India
  • +15 more
Apr 20, 2022

Healthy Volunteers Trial in Las Vegas, Fargo (RP7214, Placebo)

Completed
  • Healthy Volunteers
  • Las Vegas, Nevada
  • +1 more
Aug 17, 2021

Dry Eye Disease Trial (KIO-101)

Not yet recruiting
  • Dry Eye Disease
  • (no location specified)
Nov 17, 2022

MDS, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia Trial (RP7214)

Not yet recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • (no location specified)
Aug 17, 2022

Leukemia Trial in France, United States (BAY2402234)

Terminated
  • Leukemia
  • Bronx, New York
  • +4 more
Dec 20, 2021

Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Worldwide (JNJ-74856665, AZA, VEN)

Active, not recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Birmingham, Alabama
  • +22 more
Jan 27, 2023

COVID-19 Trial in Chertsey (leflunomide)

Active, not recruiting
  • COVID-19
  • Chertsey, United Kingdom
    Ashford and St Peters Hospital NHS Foundation Trust
Aug 12, 2021

COVID-19 Trial in India (Brequinar Sodium, Dipyridamole 75 MG, Placebo)

Terminated
  • COVID-19
  • Brequinar Sodium
  • +2 more
  • Srikakulam, Andhra Pradesh, India
  • +6 more
Jun 16, 2022

Mechanistic Studies of Teriflunomide in RRMS

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Ann Arbor, Michigan
    University of Michigan
Jul 27, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Laboratory Biomarker Analysis, Leflunomide,

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Oct 4, 2021

Alopecia Areata Trial in United States (Farudodstat, Placebo)

Recruiting
  • Alopecia Areata
  • Birmingham, Alabama
  • +18 more
May 23, 2023

Multiple Sclerosis, Relapsing-Remitting Trial in Worldwide (IMU-838 tablets, Placebo matching IMU-838 tablets)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • IMU-838 tablets
  • Placebo matching IMU-838 tablets
  • Altamonte Springs, Florida
  • +28 more
Jul 29, 2022

Leukemia, Myeloid, Acute, AML Trial in United States (PTC299)

Terminated
  • Leukemia, Myeloid, Acute
  • AML
  • Aurora, Colorado
  • +16 more
Jan 18, 2022

Multiple Sclerosis Trial in Worldwide (IMU-838 tablets, Placebo matching IMU-838 tablets)

Recruiting
  • Multiple Sclerosis
  • IMU-838 tablets
  • Placebo matching IMU-838 tablets
  • Phoenix, Arizona
  • +58 more
Jan 31, 2023

Lymphoma Trial in United States (AG-636)

Terminated
  • Lymphoma
  • New Haven, Connecticut
  • +5 more
Aug 21, 2020

COVID-19 Trial in United States (Brequinar, Standard of Care)

Completed
Has Results
  • COVID-19
  • Hartford, Connecticut
  • +4 more
Feb 15, 2022

COVID-19 Infection Trial in United States (Brequinar, Placebo)

Completed
Has Results
  • COVID-19 Infection
  • Homewood, Alabama
  • +13 more
Apr 14, 2022

MEN1 Gene Mutation Trial in Basel (Leflunomide 20 mg)

Not yet recruiting
  • MEN1 Gene Mutation
  • Leflunomide 20 mg
  • Basel, Switzerland
    Unispital Basel
Nov 1, 2022

Keratoconjunctivitis Trial in Vienna (PP-001, Placebo)

Unknown status
  • Keratoconjunctivitis
  • Vienna, Austria
    University Hospital Vienna
Mar 10, 2020

Acute Myeloid Leukemia Trial in Australia, Singapore, United States (ASLAN003)

Completed
Has Results
  • Acute Myeloid Leukemia
  • Louisville, Kentucky
  • +7 more
Jul 2, 2021

Non-infectious Uveitis Trial in Worldwide (PP-001)

Unknown status
  • Non-infectious Uveitis
  • Vienna, Austria
  • +8 more
Mar 10, 2020

Relapsing-Remitting Multiple Sclerosis (RRMS) Trial in Worldwide (IMU-838 (30 mg/day), IMU-838 (45 mg/day), Placebo)

Active, not recruiting
Has Results
  • Relapsing-Remitting Multiple Sclerosis (RRMS)
  • IMU-838 (30 mg/day)
  • +3 more
  • Blagoevgrad, Bulgaria
  • +37 more
Jan 19, 2022

Healthy Elderly Subjects (Age =55 Years) Trial in Singapore (ASLAN003, Matched Placebo)

Completed
  • Healthy Elderly Subjects (Age ≥55 Years)
  • Singapore, Singapore
    (unnamed)
Oct 31, 2016